Kelsey Goodwin Analyst Performance

Analyst at Summit Redstone

Kelsey Goodwin is a stock analyst at Summit Redstone, covering 9 publicly traded companies across a range of sectors. Over the past year, Kelsey Goodwin has issued 13 stock ratings, including buy and hold recommendations. While full access to Kelsey Goodwin's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Kelsey Goodwin's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rating: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 13 Last 0 Years
Buy Recommendations: 91.67% 11 Buy Ratings
Companies Covered: 9 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	91.7%	11 ratings
Hold	8.3%	1 ratings
Sell	0.0%	0 ratings

Out of 12 total stock ratings issued by Kelsey Goodwin at Summit Redstone, the majority (91.7%) have been Buy recommendations, followed by 8.3% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	100.0% of companies on NASDAQ	9 companies

Kelsey Goodwin, an analyst at Summit Redstone, currently covers 9 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 9 companies	100.0%

Kelsey Goodwin of Summit Redstone specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 7 companies	77.8%
MED - DRUGS 2 companies	22.2%

Time Frame

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
SMMT Summit Therapeutics	8/19/2025	Set Price Target	$25.11	$21.00
NUVL Nuvalent	8/19/2025	Initiated Coverage	$75.01	$112.00	Overweight
RVMD Revolution Medicines	8/18/2025	Initiated Coverage	$36.45	$75.00	Overweight
JANX Janux Therapeutics	8/18/2025	Initiated Coverage	$25.53	$42.00	Overweight
SMMT Summit Therapeutics	8/18/2025	Initiated Coverage	$26.29	$21.00	Neutral
CGON CG Oncology	8/18/2025	Initiated Coverage	$26.13	$55.00	Overweight
URGN Urogen Pharma	8/18/2025	Initiated Coverage	$19.40	$36.00	Overweight
TNGX Tango Therapeutics	8/18/2025	Initiated Coverage	$7.22	$11.00	Overweight
BCAX Bicara Therapeutics	8/18/2025	Initiated Coverage	$11.47	$36.00	Overweight
URGN Urogen Pharma	6/13/2025	Reiterated Rating	$11.80	$30.00	Buy
URGN Urogen Pharma	4/29/2025	Reiterated Rating	$11.21		Buy
IPSC Century Therapeutics	3/28/2025	Reiterated Rating	$0.55		Buy
IPSC Century Therapeutics	3/21/2025	Lower Price Target	$0.55	$5.00	Buy

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.